Apabetalone - Resverlogix

Drug Profile

Apabetalone - Resverlogix

Alternative Names: RVX-000222; RVX-208

Latest Information Update: 11 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Resverlogix Corporation
  • Class Anti-inflammatories; Cardiovascular therapies; Quinazolines; Small molecules
  • Mechanism of Action Bromodomain and extraterminal domain protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol
  • Phase II Prediabetic-state
  • Preclinical HIV infections; Renal failure
  • No development reported Alzheimer's disease

Most Recent Events

  • 07 Jun 2018 Apabetalone - Resverlogix is available for licensing as of 07 Jun 2018. www.resverlogix.com
  • 07 Jun 2018 Preclinical trials in HIV infections in Canada before June 2018 (for HIV-1 eradication)
  • 19 Mar 2018 Resverlogix Corporation completes enrolment in the phase III BETonMACE trial in Low HDL cholesterol (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top